Arrhythmogenic right ventricular cardiomyopathy type 1 (ARVD1) is an autosomal dominant disorder characterised by progressive degeneration of right ventricular myocardium, arrhythmias and risk of sudden death. By linkage analysis, we previously mapped the involved gene to chromosome 14q24.3. In the present study we report on linkage analysis of one additional and unrelated family, which enabled to confirm previous locus assignment. Another family is reported, in which genetic and clinical data suggest linkage to the same locus. Direct sequencing of DNA from individuals belonging to established ARVD1 families failed to detect causative mutations in exonic sequences of four genes (POMT2, TGFb3, KIAAA1036 and KIAA0759) expressed in the heart and which defects could possibly induce plasma membrane instability or apoptosis, key features of ARVD pathogenesis.
Introduction
Arrhythmogenic Right Ventricular Dysplasia (ARVD) is a cardiomyopathy characterised by progressive degeneration and fibrous-fatty replacement of right ventricular myocardium, 1 by arrhythmias with a left branch block pattern 2 and by increased risk of sudden death in juveniles. 1, 3 Several forms of dominant arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVD, OMIM 107970) were identified so far: ARVD1 (14q24.3), 4 ARVD2 (1q42), 5 ARVD3
(14q11-q12), 6 ARVD4 (2q32), 7 ARVD5 (3p23), 8 ARVD6
(10p12-p14) 9 and ARVD7 (10q22). 10 Mutations in the gene encoding the cardiac ryanodine receptor were recently detected in patients affected with ARVD2. 11 Attempts to identify genes involved in other dominant ARVDs were so far unsuccessful.
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Here we report on linkage analysis of a novel family affected with ARVD, which enabled to confirm previous chromosomal localisation of ARVD1. We report as well on another novel family probably belonging to the same clinical-genetic entity and on mutation screening of four candidate genes.
Materials and methods

Families
Two independent ARVD families were investigated at the Department of Cardiology of the University of Padua (Italy). Informed consent was obtained from all the family members participating in the study. Diagnostic criteria were according to McKenna et al. 16 Peripheral blood samples were collected from ARVD family members in EDTA-coated tubes and genomic DNA was prepared from nucleated blood cells, according to the salting out method. In total 35 individuals were studied, including 15 affected subjects.
Haplotype and linkage analysis PCR primers sequences for the different genetic markers were obtained from The Genome Database (http:// gdbwww.gdb.org/gdb/gdbtop.html). The following markers of ARVD1 locus were used for haplotyping and linkage studies: D14S994, D14S1036, D14S61, D14S42, D14S279, D14S983, D14S59, D14S254, D14S1020, D14S74 and D14S127. Two additional polymorphic markers (GenBank/ EMBL Data Libraries accession No. AJ422208 and AJ422209, respectively), identified between D14S74 and D14S127, were used to further refine the critical region.
The following markers were used to assess linkage to other known ARVD loci: D1S2800, D1S2850, D1S2670, D1S2785, D1S304, D1S2842 for ARVD2 critical region; D14S252, D14S257, D14S70 for ARVD3 critical region; D2S152, D2S364, D2S118, D2S117, D2S72, D2S2358 for ARVD4 critical region; D3S3610, D3S2403, D3S3613, D3S2338, D3S3659, D3S1293 for ARVD5 critical region; D10S547, D10S570, D10S191, D10S1653 for ARVD6 critical region; D10S605, D10S201, D10S1777, D10S1786, D10S1696, D10S1686, D10S1744, D10S215 for ARVD7 critical region.
The analysis of the microsatellite markers were performed as described elsewhere. 4 Two-point lod scores between ARVD and the marker loci were calculated by the MLINK programme of the LINKAGE package (vs 5.02).
The disease was assumed as autosomal dominant with both 70 and 95% penetrance and with a frequency of 0.01 in the population. Equal allele frequencies for the markers tested were assumed. FASTMAP programme was used to perform multipoint linkage analysis.
Bioinformatic analysis of the ARVD1 critical region
The sequence of the entire critical region was obtained from the working draft of the human genome sequence (http://genome.ucsc.edu). Annotated known genes, expressed-sequence tags (ESTs) and cDNAs were searched for in this genomic sequence. Their expression in the human heart tissue was established according to Unigene (http://www.ncbi.nlm.nih.gov/UniGene/Hs.Home.html) and STACK (http://juju.egenetics.com/stackpack/webblast.html) databases.
Reconstruction of the genomic structure of candidate genes The genomic structures of POMT2, TGFb3, KIAA1036 and KIAA0759 were reconstructed by direct comparison of their full length cDNAs with the sequence of human chromosome 14 genomic clones, retrieved from the GenBank/htgs database (http://www.ncbi.nlm.nih.gov) by BLASTN search. RT -PCR For RT -PCR analysis, PCR amplification was performed with cDNA (from human adult myocardium) as template, by using the following primers. Primer KIAA1036F, 5'-TC-GGACCCTAATTCACCTTA-3'; KIAA1036R, 5'-TCCCTGTGT-GATTGTACTGC-3'; KIAA0759F, 5'-ATTGGAACTATCGCTC-CGTG-3'; KIAA0759R, 5'-TCTGGTAAAGCTGATGGGAG-3'; TGFb3F, 5'-GTGGAAGCCATTAGGGGACA-3', TGFb3R, 5'-ATTCCGCTTAGAGCTGGGGT-3'; POMT2F, 5'-ATCAGGGC-CTACGCTTCTCA-3', POMT2R, 5'-GTCCCACAGAATGCCT-GTCA-3' PCR experiments were carried out in a reaction buffer (12.5 ml) containing 2 ml of cDNA derived from 5 mg total RNA, 5 pMoli oligonucleotide primers, 1 ml DMSO and 0.2 U of Taq DNA polymerase (ExperTeam). An aliquot of the amplified products was subjected to 2% agarose gel electrophoresis and stained by ethidium bromide. Amplified products were visualised by UV light. RT -PCR products were then subjected to direct DNA sequencing analysis.
Mutation screening PCR primers flanking the exons of each candidate gene for amplification from genomic DNA for mutation screening were designed by PRIMER3 (http://www-genome.wi.mit.edu). The sequences of primers are listed in Table 4 . Mutation screening was performed by direct sequencing of both strands. Each exon was amplified from patient genomic DNA, purified (PCR Product Pre-Sequencing kit; USB) and sequenced using the BIG DYE dideoxy-terminator chemistry (Perkin Elmer) on an ABI 377 DNA sequencer (PE Applied Biosystems). Chromas 1.5 software (Technelysium) and LASERGENE package computer programmes (DNAS-TAR) were used to edit, assemble and translate sequences.
Results
Clinical data
A family (Fam. 112) from Northern Italy, showing recurrence of ARVD cases and unrelated to those described in the original article 4 was investigated. Clinical features, summarized in Table 1A , fitted a 'classical' form of ARVD.
Linkage analysis
Pedigree of family 112 is shown in Figure1A, along with haplotypes corresponding to part of chromosomal region 14q24.3-q31.1. Two point lod scores for 11 microsatellite markers are shown in Table 2 . Maximum lod scores at y=0
(assuming 95% of penetrance) were obtained with marker D14S254 (Z=4.41), and marker D14S983 (Z=4.06). The 'affected only' lod score resulted close to the level of significance (2.71 for markers D14S983 and D14S59, at y=0).
Multipoint linkage analysis (peak lod score Z=5.20) suggested that the most likely location of ARVD1 is between D14S279 and D14S283 (data not shown). Unfortunately, no recombinants were detected in the family.
An additional family (Family 119, Figure 1B ), from South Germany, was investigated because patients showed clinical features consistent with the hypothesis of ARVD1 (Table  1B) .
Preliminary haplotype investigation, by means of a panel of markers for each of the ARVD loci identified so far, showed that segregation was consistent only with the hypothesis of association of the disease to ARVD1 locus. Haplotype sharing analysis was performed on affected members of Family 119 and on their relatives, by using the same microsatellite markers tested in Family 112. The at-risk haplotype of Family 119 resulted differently from that detected in Family 112.
In family 119, affected individuals II, 6 and III, 2 showed recombinations between markers D14S74 and D14S127 and between D14S1036 and D14S61, respectively ( Figure 1B ). Small size of family 119 failed to produce significant lod scores by linkage analysis. However, it is worth noticing that a lod score of 1.51 was obtained for marker D14S59.
Mutation screening of candidate genes
Mutation screening on coding sequences of four candidate genes (POMT2, TGFb3, KIAA0759 and KIAA1036) included in the ARVD1 critical region was attempted. Mutations in three of the selected genes could possibly induce plasma membrane instability or apoptosis, which are presently believed as primary steps in ARVD pathogenesis 4,16 -18 ; the fourth gene was considered because it is expressed in heart, although its function is still unknown.
After genomic structure of these genes was determined by gapped BLAST comparison of cDNA sequences with genomic DNA sequences available in GenBank, PCR primers were designed. RT -PCR on total RNA extracted from normal human heart demonstrated that all these genes are expressed in cardiac tissue (data not shown). Data about the four candidate genes are summarized in Table 3 .
PCR primers (Table 4) , designed to flank each exon, were used to screen genomic DNA from two ARVD1 patients, belonging to the two ARVD1 families identified so far in our laboratory (Fam 100 of the previous study and Fam 112, this study) and from one healthy control subject. POMT2, TGFb3, KIAA1036 and KIAA0759 coding sequences O-mannosylation plays an essential role in a number of physiologically important processes, 75829352) among which is maintenance of cell wall integrity. Four domains present as a triplet in O-mannosyltransferases (MIR domain) are found also in the N-terminals of Ryanodine receptors (RyRs) and inositol 1, 4, 5-triphosphate receptors (IP3Rs). O-mannosyltransferases transfer mannose from DOL-P-mannose to ser or thr residues on proteins [19] . The presence of an uncommon O-linked mannosyl glycan was found in bovine peripheral nerve and rabbit skeletal muscle a-dystroglycans [20, 21] , an extracellular peripheral membrane glycoprotein binding to a transmembrane glycoprotein, b-dystroglycan. The a-dystroglycan -b-dystroglycan complex acts as a transmembrane linker between the extracellular matrix and intracellular cytoskeleton [22] . TGFb3 D14S61 23 7 TGFb is a multifunctional cytokine. The protein is an homodimer, disulfide-linked. TGFb is known (74466566 -D14S270 to modulate several tissue development and repair processes, including cell differentiation, cell 74489613) cycle progression, cellular migration, cell adhesion, and extracellular matrix production. The different effects of TGFb are mediated by the TGFb receptors and cell surface-binding proteins [23] . TGFb is a potent growth inhibitor and inducer of apoptosis [24] . KIAA0759 D14S42 25.6 10 The amino acid sequence of the predicted protein product is 83% identical and 86% similar to (75270912 -D14S279 the Mus musculus unknown protein AAH19148 and 42% identical and 56% similar to the 75291491) hypothetical human protein XP034232. The hydropathy analysis of the protein sequence indicated the presence of a hydrophobic region that could form a transmembrane domain. KIAA0759 was found to contain an RGD motif. The sequence Arg-Gly-Asp (RGD), found in fibronectin, is crucial for its interaction with its cell surface receptor, an integrin [25] [26] and it was also found in the sequences of a number of other proteins (some forms of collagens, fibrinogen, vitronectin, von Willebrand factor (VWF), snake disintegrins, and slime mold discoidins), where it has been shown to play a role in cell adhesion. Function of this gene is unknown. KIAA1036 D14S42 20.6 7 No significant sequence homology was identified using the BLAST server. No obvious structural (75270912 -D14S279 features or motifs were found. Several potential phosphorylation and N-glycosylation sites are 75291491) present. Sequence analysis with the TM-pred program showed no significant transmembrane helices. Function of this gene is unknown.
ARVD1 locus confirmed
were screened for mutations by sequencing exons and intron-exon boundaries. Although single-nucleotide substitutions were detected in these genes, no ARVD1-specific sequence alterations were identified (Table 5) .
Discussion
In one novel family fulfilling diagnostic criteria for ARVD and unrelated to those previously described, significant linkage to ARVD1 was detected. This is the first evidence confirming the early locus assignment. It is interesting to notice that no additional linkage data were reported so far for any of the other ARVD forms, if we excluded ARVD2 27 , which involved gene was recently identified in our laboratory. 11 An additional family was investigated in which haplotype analysis excluded linkage to any of known ARVD TGFb3  1  301  CTCCCAGCTCCAGTTCAGAC  AGAAGAGGGTGGAAGCCATT  65  307  GTAAAGGGCCAGGACCTGAT  TGGTTTTCCTCCCTCCTTCT  65  2  281  TATGGCAAAGGAACCAGCTT  GCACACTGTTCCTGCATGTC  65  3  326  TGTCCTCTTCCCTCCATTTCA  CATGGCATTCAGGAACCACT  60  4  233  CTTTTGGGGCAAAGCAGATT  CCCTATAGGAGCAGAGGCCC  68  5  319  ACCCTCTGTTGAGTGTGGCT  GGGCTCTGCTCTCTTCAGAC  60  6  307  AACAAGTGGTCTGGTCGGTC  CATGAAAGGACTCCAAGGGA  62  7  285  TGTTGCTTGTGTGTTTCCC  CTGAGACTTGGCCTTCCAAC  62  325  CCCTTCCTTCTCCCTTTAG  GAGAGAGAACCACCACTGCC  58  KIAA0759  1  234  GGGCACGGTAGTCGTGAG  GAGCTGAGGGAGGACCTG  65  2  423  CTCTTTAGCAATGGCTCTTGC  GAGAATGCTCGCTTCAGAGGA  62  393  AAGGCTCATCCAGGTTCTCT  TGGGCTTATGTTTTAGCTGG  62  3  373  TTCTAAGAGCACTGGGCAAC  TGAGTCAGGAGTGGAGATGG  58  4  205  ATGGGGTCTTCAGGAGAGAG  CTAGAGGGTGGGGGTCAC  58  5  352  TGCTAACGCCTGAATCTCTC  GGGCTTAGTGTTGCTACTGC  58  360  ATCTGGGCCAGCTTGACAT  CATACACTGGGACTGCTGGT  62  6  270  GTCGTTGAGACACCAGCTTT  CCAAAACATGGGCTGTTACT  58  7  258  TGACCAATATCAGGAATGAGG  TATGCTGGAAGTTGCTTGGT  58  8  210  TGGGAATCTCTCTCTTACACCT  TTAGGGTGAAAGGTTCTGAT  58  9  308  GCTACCAAATGCCTGACCTA  AGAAAAAGTGATCTAGGGAAAA  58  10  300  TTTCCACAGTCTCTGATCCA  AGGACTCTGCCACTGCCT  62  KIAA1036  1  404  CCTCTTGTGAGCCAGTTGTT  CCTAGACTGTGCTATCACCC  58  2  168  ACTGGAAGCTCCAAGGTGA  GACCCTTGACCAGAGAGGAT  58  3  166  AGAGGGTCAACCTCCTTCAG  TTTCAAGAAGCTCCAAGCC  55  4  194  TCCTTCTCACATTCCCCTG  AGCTGAGGCCCAGAGAAG  58  5  497  CGTGCTTCTCCTGGCTCT  CAATCCTCACATCGCCTCT  58  6  240  CTGGAAGGAGAGGTTGGG  CGATGAGAGAGGAAAGGAAAAA  58  7  269  CCATCTCCCTAACAGACCAC  GGCTGAGCTGGAACACACT  58 ARVD1 locus confirmed A Rampazzo et al 74 loci, except ARVD1. However, the small size of the family impeded to obtain significantly positive lod scores by linkage analysis. The at-risk haplotype in this family appeared different from that detected in Family 112. This is not surprising, due to the different geographical origin of the two families. If we would accept that the disease in family 119 is linked to ARVD1 locus, recombinations detected in this family (between disease and D14S1036 and D14S127) would narrow the ARVD1 critical region to approximately 7.9 Mb.
The critical interval for ARVD1 is very large. Nevertheless, we attempted to screen for ARVD1-causing mutations coding sequences of four genes (POMT2, TGFb3, KIAA1036 and KIAA0759), after having proved that they are expressed in the heart. These genes were selected on the basis of the possible role of their mutations in ARVD pathogenesis, as suggested by identification of pathogenic mutations in the gene encoding cardiac Ryanodine receptor (RYR2/ARVD2) and in the Plakoglobin gene (JUP, involved in Naxos disease, an autosomal recessive form of ARVD). Actually, mutations in three selected genes might produce plasma membrane instability or apoptosis, which are presently believed to be primary steps in ARVD pathogenesis 4, 16 -18 , while fourth gene was considered because it is placed in the region corresponding to the maximum location score, it is expressed in the heart tissue and its function is still unknown.
Mutation screening of the coding regions and of intronexon boundaries of all these genes revealed only non pathogenic sequence variants. However, the presence of intragenic deletions or of regulatory mutations in one of these genes cannot be ruled out at this moment.
Restriction of the critical ARVD1 region is essential for the progress of the investigation aiming at the identification of the involved gene. Hopefully, two research initiatives on ARVD, recently launched by European Community and by US National Health Institute, should succeed in reaching this goal soon. 
